Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoglitazone Monotherapy in Type 2 Diabetes
NCT00484198Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of rivoglitazone in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Hemoglobin A1c at 26 weeks and Change in Hemoglobin A1c at 26 weeks. Started Apr 2007; status: completed.
02
Drugs
rivoglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00484198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00484198.